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The development of nitric oxide (NO)- and hydrogen sulfide (H2S)-releasing
nonsteroidal anti-inflammatory drugs (NSAIDs) has generated more potent
anti-inflammatory drugs with increased safety profiles. A new hybrid molecule
incorporating both NO and H2S donors into aspirin (NOSH-aspirin) was
recently developed. In the present study, the antinociceptive activity of this
novel molecule was compared with aspirin in different models of inflammatory
pain. It was found that NOSH-aspirin inhibits acetic acid-induced writhing
response and carrageenan (Cg)-induced inflammatory hyperalgesia in a dose-
dependent (5–150 lmol/kg, v.o.) manner, which was superior to the effect of
the same doses of aspirin. NOSH-aspirin’s antinociceptive effect was also
greater and longer compared to aspirin upon complete Freund’s adjuvant
(CFA)-induced inflammatory hyperalgesia. Mechanistically, NOSH-aspirin, but
not aspirin, was able to reduce the production/release of interleukin-1 beta
(IL-1b) during Cg-induced paw inflammation. Furthermore, NOSH-aspirin,
but not aspirin, reduced prostaglandin E2-induced hyperalgesia, which was pre-
vented by treatment with a ATP-sensitive potassium channel (KATP) blocker
(glibenclamide; glib.). Noteworthy, the antinociceptive effect of NOSH-aspirin
was not associated with motor impairment. The present results indicate that
NOSH-aspirin seems to present greater potency than aspirin to reduce inflam-
matory pain in several models. The enhanced effects of NOSH-aspirin seems to
be due to its ability to reduce the production of pronociceptive cytokines such
as IL-1 b and directly block hyperalgesia caused by a directly acting hyperalgesic
mediator in a mechanism dependent on modulation of KATP channels. In con-
clusion, we would like to suggest that NOSH-aspirin represents a prototype of
a new class of analgesic drugs with more potent effects than the traditional
NSAID, aspirin.
Abbreviations
ANOVA, analysis of variance; CFA, complete Freund’s adjuvant; H2S, hydrogen sul-
fide; IL-1b, interleukin-1 beta; KATP, ATP-sensitive potassium channel; KC/CXCL1,
keratinocyte-derived chemokine; MPO, myeloperoxidase; NO, nitric oxide; NSAIDs,
nonsteroidal anti-inflammatory drugs; PGE2, prostaglandin E2; TNF-a, tumor
necrosis factor.
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Introduction
Inflammatory pain is one of the most common symp-
toms of the inflammatory disease and represents an
important health problem. It is principally caused by the
sensitization of primary nociceptive neurons by the direct
action of inflammatory mediators (e.g., prostaglandins).
In this context, pharmacologic control of inflammatory
pain is mainly based on the use of nonsteroidal anti-
inflammatory drugs (NSAIDs; aspirin and aspirin like
drugs), which inhibits cyclooxygenase-derived prostaglan-
din production and, consequently, reduces nociceptor
sensitization (Ferreira 1972, 1980; Ferreira and Vane
1974). This effect ultimately prevents the development of
hyperalgesia (decrease in nociceptive threshold) in
humans and animals. However, NSAIDs are only partially
effective and prolonged exposure can cause serious gas-
trointestinal (GI), renal, and cardiovascular side effects
(Kashfi 2009). Thus, there is continuous effort to identify
novel therapeutics for pain control that elicits fewer side
effects.
A second strategy to control inflammatory pain is
through the use of drugs, which are able to directly
block ongoing nociceptor sensitization through periph-
eral actions (Lorenzetti and Ferreira 1985; Ferreira et al.
1991; Duarte et al. 1992). In fact, local administration of
opioids and dipyrone reversed already established hyper-
algesia induced by prostaglandin E2 (PGE2) (Ferreira
1972; Lorenzetti and Ferreira 1996). Therefore, in con-
trast to NSAIDs, drugs that act through the prevention
of nociceptor sensitization by inhibiting prostaglandin
synthesis are able to reverse ongoing inflammatory
hyperalgesia.
In order to elucidate the mechanism involved in the
directly blockage of ongoing inflammatory hyperalgesia,
inhibitors of neuronal nitric oxide (NO) synthase as well
as ATP-sensitive potassium channel (KATP) potassium
channels blockers prevented peripheral antinociception
achieved with opioids and dipyrone (Rodrigues and
Duarte 2000; Soares and Duarte 2001; Sachs et al. 2004).
Therefore, it was suggested that this antinociceptive effect
is mediated by NO and KATP. Corroborating with this
fact, the direct blockade of ongoing mechanical hyperalge-
sia has been observed after administration of NO donors,
SNAP and sodium nitroprusside as well as KATP channels
openers (Soares et al. 2000). Besides NO donors, it has
also been described that hydrogen sulfide (H2S) donors
are also able to directly block ongoing inflammatory
hyperalgesia through the modulation of KATP currents
(Distrutti et al. 2006a; Zanardo et al. 2006; Cunha et al.
2008a). Thus, these types of peripheral analgesics seem to
act by restoring the threshold of nociceptors via the
increase in KATP permeability promoting the hyperpolar-
ization of primary nociceptive neurons (Distrutti et al.
2006a; Cunha et al. 2008a).
In attempt to enhance the activity of NSAIDs and to
minimize their potential side effect, novel NSAIDs hybrids
have been developed (Kashfi 2009; Qandil 2012). NO-
releasing NSAIDs have been shown to be effective in pre-
clinical models of inflammation with less side effects and
they have been evaluated in several clinical trials (Schnit-
zer et al. 2005; Fiorucci and Distrutti 2011). Similarly,
H2S-releasing NSAIDs have been shown to have anti-
inflammatory properties (Kashfi and Olson 2013). Based
on the scientific evidence that NO and H2S are gaseous
mediators with physiological relevance, a new hybrid
incorporating these two entities into an aspirin molecule
was developed, the so-called NOSH-aspirin (Kodela et al.
2012). NOSH-aspirin was shown to be more efficient
and/or powerful than traditional aspirin in several experi-
mental models (Kodela et al. 2012). For instance, NOSH-
aspirin was a potent inhibitor of colon cancer cell growth
in vitro and in an in vivo model of human colon cancer
xenografts in mice (Chattopadhyay et al. 2012). Further-
more, NOSH-aspirin was more potent than aspirin to
attenuate microglial and astrocytes activation in an in vitro
model of neuroinflammation (Lee et al. 2013). Based on
the above evidences, in the present study we investigated
the possible analgesic effects of NOSH-aspirin in several
inflammatory models of pain, comparing it to aspirin.
Material and Methods
Animals
The experiments were performed on male Balb/C mice
weighing between 20 and 30 g. The mice were housed in
the animal care facility of the Ribeirao Preto Medical
School and moved to the testing room at least 1 h before
the experiments. Food and water were available ad libitum.
Behavioral tests were performed on animals in a random-
ized order in a blind fashion in which the person who
performed the treatments was not the same as one who
made the behavioral assessment. Animal care and han-
dling procedures were in accordance with the guidelines
of the International Association for the Study of Pain
(IASP) on the use of animals in pain research, and with
the approval of the Ethics Committee of the Ribeirao
Preto Medical School, University of S~ao Paulo.
Chemicals and drugs
The following drugs and chemicals were obtained from
the sources indicated: PGE2, glib., complete Freund’s
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adjuvant (CFA), aspirin and diazepam were from Sigma-
Aldrich (St. Louis, MO); Cg (FMC Corp., Philadelphia,
PA); acetic acid, dimethylsulfoxide (DMSO) and Tween
20 were from Merck (Darmstadt, Germany); NOSH-aspi-
rin (Fig. 1) [4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-
(nitrooxy)butanoyl) oxy)benzoate] was synthesized and
characterized as previously described (Kodela et al. 2012)
and was a gift from Avicenna Pharmaceuticals (New
York, NY). The drugs were prepared as follows: glib. was
dissolved in 1% Tween 20 in saline; PGE2 was dissolved
in 2% ethanol in saline; diazepam was dissolved in saline;
aspirin and NOSH-aspirin were dissolved in DMSO/
Tween 20 and resuspended in saline. The final concentra-
tions of DMSO and Tween 20 were 5%.
Acetic acid-induced writhing test
Mice were treated by gavage (p.o.) with aspirin (5, 15 or
150 lmol/kg), NOSH-aspirin (5, 15, or 150 lmol/kg) or
vehicle an hour before testing. Writhing responses were
induced by intraperitoneal (i.p.) injection of acetic acid
0.8% (100 lL per 10 g body weight). The numbers of
writhing responses were counted during a 20-min period as
reported previously (Collier et al. 1968). The writhing
response consists of a contraction of the abdominal muscle
together with a stretching of hind limbs. The inhibitory
effects were calculated based on the effect of the vehicle.
Evaluation of mechanical hyperalgesia:
electronic von Frey test
In this study, we have used the term hyperalgesia to
describe the decrease in the mechanical nociceptive
threshold of mice. Mechanical hyperalgesia was tested as
previously reported (Cunha et al. 2004). Briefly, in a quiet
room, mice were placed in acrylic cages
(12 9 20 9 17 cm) with wire grid floors, 15–30 min
before the start of the test. The test consisted of evoking a
hind paw flexion reflex with a hand-held force transducer
adapted with a 0.5-mm2 polypropylene tip for mice (Elec-
tronic von Frey; IITC Life Science, Woodland Hills, CA).
A tilted mirror placed under the grid provided a clear
view of the mice hind paw. The investigator was trained
to apply the tip in between the five distal footpads with a
gradual increase in pressure. The stimulus was automati-
cally discontinued and its intensity recorded when the
paw was withdrawn. The end-point was characterized by
the removal of the paw in a clear flinch response after
paw withdrawal. The animals were tested before and after
treatments. A different investigator performed each test,
as was the case in the preparation of solutions and treat-
ment of the animals. The results are expressed by the D
mechanical threshold (in grams, g), which was calculated
by subtracting the average of the last three measurements
after treatments from the average of three measurements
before treatments.
Effect of NOSH-aspirin on inflammatory
hyperalgesia
In attempt to compare the antinociceptive effects of aspi-
rin and NOSH-aspirin on inflammatory hyperalgesia, ini-
tially, we evaluated the dose–response effects of these
drugs against Cg-induced acute mechanical inflammatory
hyperalgesia. The animals were pretreated (30 min before)
with NOSH-aspirin (5, 50 and 150 lmol/kg, p.o.), aspirin
(5, 50, and 150 lmol/kg, p.o.), or vehicle (p.o.) followed
by intraplantar (i.p.) injection of Cg (100 lg/paw).
Mechanical hyperalgesia was determined 3 h after Cg
injection using electronic von Frey. This time point corre-
sponds to the maximal hyperalgesia produced by Cg. Fur-
thermore, to evaluate the effect of these drugs on long-
lasting mechanical inflammatory hyperalgesia, CFA was
injected first (10 lL/paw), after 24 h the animals were
treated orally with NOSH-aspirin (150 lmol/kg, p.o.),
aspirin (150 lmol/kg, p.o.) or vehicle and then mechani-
cal hyperalgesia was evaluated at 1, 3, 5, 7, and 24 h post
drugs treatment as described above. As a control we used
i.p. injection of saline.
Effect of NOSH-aspirin on hyperalgesia
produced by a directly acting hyperalgesic
mediator: involvement of KATP
In attempting to verify whether NOSH-aspirin was able
to affect hyperalgesia produced by a directly acting medi-
Figure 1. Structural components of NOSH-aspirin. The parent
compound aspirin is shown in the shaded box. The parts of the
molecule that releases NO and H2S are shown in the dotted ellipses.
NO, nitric oxide; H2S, hydrogen sulfide.
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ator, its effect on PGE2-induced hyperalgesia was evalu-
ated. Mice were pretreated 50 min before with aspirin
(150 lmol/kg), NOSH-aspirin (150 lmol/kg) or vehicle
orally followed by i.p. injection of PGE2 (100 ng/paw).
Mechanical hyperalgesia was evaluated 60 min after injec-
tion of PGE2, which correspond to the maximal hyperal-
gesic response produced by PGE2 (Cunha et al. 2008b).
To ascertain whether the actions of NOSH-aspirin were
mediated through KATP, mice were pretreated with a KATP
blocker, glib. (10 mg/kg, i.p.) and after 30 min, they
received vehicle or NOSH-aspirin (150 lmol/kg) orally.
After 50 min all groups received i.p. injection of PGE2.
Mechanical hyperalgesia was evaluated 60 min after injec-
tion of PGE2.
Determination of neutrophil accumulation
in the inflammatory site
Myeloperoxidase (MPO) activity was used as an index
of neutrophil accumulation in the mice’s plantar tissues,
based on a kinetic-colorimetric assay as described previ-
ously (Bradley et al. 1982). Mice were pretreated with
NOSH-aspirin (150 lmol/kg, v.o.), aspirin (150 lmol/kg,
v.o.) or vehicle followed by i.p. injection of Cg (100 lg/
paw). Plantar tissue was harvested from the injected and
control paws (saline). Samples were collected in
50 mmol/L K2HPO4 buffer (pH 6.0) containing 0.5%
hexadecyl trimethylammonium bromide and kept at
80°C. Just before the assay, the tissue was homoge-
nized using a Polytron (PT3100) and centrifuged at
13,000 g for 4 min. In our experimental condition (low
pH), the MPO assay did not detect the activity of this
enzyme in mononuclear cells. To prepare the solution
for the analysis, 5 lL of the supernatant was mixed with
200 lL of phosphate buffer (50 mmol/L, pH 6.0), con-
taining 0.167 mg/mL O-dianisidine dihydrochloride and
0.0005% hydrogen peroxide. The solution was analyzed
by spectrophotometry for MPO activity determination at
450 nm (Spectra max, Molecular Devices, Sunnyvale CA,
USA). The MPO activity was compared with a standard
curve of neutrophils obtained from mice blood. The
results were presented as number of neutrophils 9106/
mg tissue.
Cytokine measurements
Mice were pretreated with NOSH-aspirin (150 lmol/kg,
v.o.), aspirin (150 lmol/kg, v.o.) or vehicle orally fol-
lowed by i.p. injection of Cg (100 lg/paw). Plantar tissue
was harvested from the injected and control paws (saline)
3 h after Cg injection. The time for cytokine
measurement was defined based on the peak of the pro-
duction of the analyzed cytokines (Cunha et al. 2005).
The samples were triturated and homogenized in 300 lL
of the appropriate buffer containing protease inhibitors.
The concentrations of the cytokines tumor necrosis fac-
tor-a (TNF-a), interleukin-1 beta (IL-1b), and keratino-
cyte-derived chemokine (KC/CXCL1) were determined as
previously described by ELISA (Cunha et al. 2005) using
paired antibodies (R&D Systems, Minneapolis, MN,
USA). The results are expressed as pg/paw of each
cytokine.
Measurement of motor performance
In order to discard possible nonspecific muscle relaxant
or sedative effects of NOSH-aspirin, mice motor perfor-
mance was evaluated on the rota-rod test (Rosland et al.
1990). The apparatus consisted of a bar with a diameter
of 2.5 cm, subdivided into six compartments by disks
25 cm in diameter (Model 7600; Ugo Basile, Varese,
Italy). The bar rotated at a constant speed of 22 rotations
per minute. The animals were selected 24 h previously by
eliminating those mice that did not remain on the bar for
two consecutive periods of 120 sec. Animals were treated
orally with vehicle or NOSH-aspirin (150 lmol/kg, v.o.).
Diazepam (5 mg/kg, i.p.) was used as a positive control.
The animal’s latency to fall off was measured automati-
cally by a mechanical sensor located in the floor of the
apparatus. The cut-off time used was 120 sec.
Statistical analysis
Data are reported as the means  SEM and are represen-
tative of two separate experiments. The letter n in the leg-
ends refers to the number of mice used in the
experimental group of each experiment. The differences
between the experimental groups were compared by one-
way analysis of variance (ANOVA), and individual com-
parisons were subsequently made with Tukey’s post hoc
test. Two-way ANOVA was used to compare the groups
when the hypernociceptive responses were measured at
different times after the stimulus injection. A value of
P < 0.05 was considered significant.
Results
NOSH-aspirin reduced acetic acid-induced
writhing responses in mice: Comparison
with aspirin
Intraperitoneal injection of acetic acid-induced writhing
response has been extensively used in the screening of
novel analgesic drugs (Collier et al. 1968). Thus, this
nociceptive behavior test was initially used to evaluate
the possible antinociceptive effect of NOSH-aspirin in
2015 | Vol. 3 | Iss. 3 | e00133
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comparison to that of aspirin. NOSH-aspirin and aspirin
were both effective in inhibiting acetic acid-induced
writhing response in a dose-dependent manner (Fig. 2).
However, whereas only the highest dose of aspirin pre-
sented a significant effect, the low and intermediary
doses of NOSH-aspirin were significantly effective in
inhibiting the writhing responses (Fig. 2). Regarding effi-
cacy, at the highest dose tested (450 lmol/kg), inhibition
due to aspirin was ~49%, while in the NOSH-aspirin-
treated animals this effect reached ~59% (Fig. 2).
Although NOSH-aspirin’s effect was higher than aspirin
at this dose no statistical difference (P = 0.089) was
observed.
NOSH-aspirin did not produce significant
impairment in mice motor coordinance
It is important to note that sedative agents may produce
false-positive effects on the acetic acid-induced writhing
response test (Lopes et al. 2013). In this context, we used
the rota-rod test to evaluate whether the antinociceptive
effect of NOSH-aspirin upon acetic acid-induced writhing
response might be due to an unspecific effect on motor
coordinance. Importantly, NOSH-aspirin (150 lmol/kg,
p.o.) did not change locomotor activity in all evaluated
times. As a positive control, Diazepam produced signifi-
cant motor impairment (Fig. 3).
NOSH-aspirin inhibits Cg- and CFA-induced
inflammatory hyperalgesia: comparison
with aspirin
Further investigating the potential antinociceptive effect
of NOSH-aspirin, we next evaluated its effect against Cg-
induced acute inflammatory hyperalgesia (Joris et al.
1987). Aspirin and NOSH-aspirin treatments were also
able to inhibit Cg-induced inflammatory hyperalgesia
(Fig. 4A and B). Similar to that observed in the acetic
acid model, whereas the intermediary dose of NOSH-
aspirin (50 lmol/kg) produced a significant effect, only
the higher dose of aspirin was able to reduce inflamma-
tory hyperalgesia (Fig. 4C). In terms of efficacy, at
50 lmol/kg, hyperalgesic inhibition due to aspirin was
~25%; whereas at the same dose, NOSH-aspirin caused a
50% inhibition (Fig. 4C). At the highest dose tested
(150 lmol/kg), inhibition due to aspirin was ~52%, while
in the NOSH-aspirin-treated animals this effect reached
~72% (Fig. 4C).
In a therapeutic perspective, next we evaluated the
posttreatment effect of NOSH-aspirin against CFA-
induced inflammatory hyperalgesia. At 24 h after i.p.
injection of CFA, mechanical hyperalgesia was measured
followed by the treatment with vehicle, aspirin and
NOSH-aspirin (150 lmol/kg; Fig. 4D). CFA-induced
inflammatory hyperalgesia was reduced by the treatment
with aspirin and NOSH-aspirin. However, the effect pro-
duced by NOSH-aspirin was initiated earlier, was greater
in magnitude, and long lasting (Fig. 4D).
Figure 2. Effect of NOSH-aspirin (NOSH-ASA) and aspirin on acetic
acid-induced writhing responses in mice. Animals were pretreated
orally (p.o.) with aspirin (5, 15, 150 lmol/kg), NOSH-ASA (5, 15, 150,
and 450 lmol/kg) or vehicle (v), 50 min before the intraperitoneal
administration of acetic acid (0.8%, i.p.). Writhing responses was
assessed during 20 min after acetic acid injection. The graphic
represents the percentage of inhibition relative to vehicle. Data are
the means  SEM (n = 7). *P < 0.05, **P < 0.01, and ***P < 0.001
versus vehicle group.
Figure 3. Effect of NOSH-aspirin (NOSH-ASA) on motor coordinance.
Mice were treated orally with NOSH-ASA (150 lmol/kg, v.o.),
diazepam (5 mg/kg, i.p.) (positive control) or vehicle and were
subjected to Rota-rod test. Sections were performed before and 1, 3,
and 5 h after treatments. Data are the means  SEM (n = 6).
*P < 0.05, **P < 0.01, and ***P < 0.001 versus vehicle group.
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Effect of NOSH-aspirin on Cg-induced
neutrophil migration and pronociceptive
cytokines production
In order to assess the mechanisms by which NOSH-aspi-
rin further inhibits inflammatory hyperalgesia compared
to aspirin, we next compared the effects of NOSH-aspirin
and aspirin on Cg-induced neutrophil migration and
pronociceptive cytokines production in the plantar tissue.
Pretreatment with aspirin or NOSH-aspirin did not affect
Cg-induced neutrophil migration in mice (Fig. 5A).
Although pretreatment with aspirin or NOSH-aspirin did
not change the production of TNF-a (Fig. 5B) or KC/
CXCL1 (Fig. 5C), NOSH-aspirin but not aspirin signifi-
cantly reduced the production of IL-1b (Fig. 5D) when
compared to the vehicle-treated group. Thus, the
enhanced antinociceptive effect promoted by NOSH-aspi-
rin when compared with aspirin may in part be due to its
ability to reduce IL-1-b production.
NOSH-aspirin directly blocks PGE2-induced
hyperalgesia: Involvement of KATP channels
NO and H2S are able to reduced inflammatory hyperalge-
sia by acting directly on neuronal excitability through
modulation of KATP channels (Soares et al. 2000; Cunha
et al. 2008a). Therefore, in the next step we evaluated
whether NOSH-aspirin was able to reduce hyperalgesia
produced by a directly acting hyperalgesic mediator,
PGE2, and whether this effect was dependent on KATP
(A) (B)
(C) (D)
Figure 4. Effect of NOSH-aspirin (NOSH-ASA) and aspirin on carrageenan- and CFA-induced inflammatory hyperalgesia. Mice were pretreated
with (A) aspirin (5, 50 and 150 lmol/kg), (B) NOSH-ASA (5, 50, and 150 lmol/kg) or vehicle (v) orally (p.o.) 30 min before the intraplantar
injection of carrageenan (Cg; 100 lg/paw). The hypernociceptive responses were evaluated 3 h after carrageenan injection. (C) Percentage of
inhibition caused by aspirin and NOSH-ASA (150 lmol/kg) upon carrageenan-induced hyperalgesia. (D) Animals received an injection of 10 lL of
CFA in the hind paw. At 24 h after, mechanical nociceptive threshold was evaluated followed by the treated with NOSH-ASA (150 lmol/kg),
aspirin (150 lmol/kg) or vehicle (p.o.). Mechanical hyperalgesia was evaluated 1, 3, 5, 7, and 24 h after treatment. Data are the means  SEM
(n = 6). *P < 0.05, **P < 0.01, and ***P < 0.001 versus vehicle-treated group. CFA, complete Freund’s adjuvant.
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channels modulation. First, it was observed that pretreat-
ment with NOSH-aspirin, but not with aspirin, was able
to reduce PGE2-induced mechanical hyperalgesia
(Fig. 6A). Furthermore, the antinociceptive effect of
NOSH-aspirin upon PGE2-induced hyperalgesia was pre-
vented when mice were treated with a KATP channels
blocker (glib.) (Fig. 6B). As a control, glibenclaminde
alone caused no change in PGE2-induced hyperalgesia
(Fig. 6B). Therefore, these results further indicate that the
additive effects of NOSH-aspirin over aspirin might be
partially due to its direct effect on inflammatory hyperal-
gesia through up modulation of KATP currents.
Discussion
NSAIDs are used to relive the most common forms of
pain and in the United States over 30 million people use
NSAIDs on a daily basis (American-Gastroenterological-
Association 2005). However, their effective pain relief
may at times be limited and their long-term use may lead
to severe side effects, including GI, cardiovascular, and
renal disorders (Ejaz et al. 2004; Patricio et al. 2013).
Thus, developing NSAIDs that offer effective pain control
with fewer or less serious adverse effects would be a valu-
able medical advance (Nalamachu et al. 2014). To address
these potentially harmful effects, NOSH-aspirin (NBS-
1120), a NO- and H2S-releasing hybrid was developed
(Kodela et al. 2012). The rational for developing NOSH-
aspirin was based on the observations that NO (Wallace
and Miller 2000) and H2S (Fiorucci 2009) have some of
the same properties as PGs within the gastric mucosa,
thus modulating some components of the mucosal
defense systems. NOSH-aspirin was shown to have potent
anti-inflammatory properties (Kodela et al. 2012) and be
devoid of any GI side effects (Nia et al. 2013). Herein, we
provide evidence that NOSH-aspirin is a novel therapeu-
(A) (B)
(C) (D)
Figure 5. Effect of NOSH-aspirin (NOSH-ASA) and aspirin on carrageenan-induced neutrophil migration and local production of pronociceptive
cytokines. Mice were pretreated with aspirin (150 lmol/kg), NOSH-ASA (150 lmol/kg) or vehicle orally 30 min before the intraplantar injection of
carrageenan (Cg; 100 lg/paw) or saline. At 3 h after Cg injection plantar tissue were collected for measurement of (A) neutrophil migration
(MPO activity assay) and the levels of (B) TNF-a, (C) KC/CXCL1, and (D) IL1-b by ELISA. Data are the means  SEM (n = 6). ***P < 0.001 versus
saline group. #P < 0.05 versus vehicle-treated group. MPO, myeloperoxidase; TNF-a, tumor necrosis factor-a; KC/CXCL1, keratinocyte-derived
chemokine.
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tic agent for controlling inflammatory pain. It was more
potent than aspirin, its parent compound and presents
long-lasting effect, in producing analgesia in different
experimental models of inflammatory pain. Moreover, it
seems that NOSH-aspirin’s-enhanced antinociceptive
effect might be due to its ability to reduce the production
of IL-1b and restore neuronal sensitization caused by
PGE2 through upregulation of KATP channels, which was
not observed with aspirin.
Initially, the acetic acid-induced writhing test was used
to investigate the in vivo antinociceptive activity of
NOSH-aspirin. This test is a visceral pain model that is
widely used to evaluate antinociceptive activity of novel
compounds (Morucci et al. 2012). In this model, nocicep-
tive behaviors are generated through direct action of ace-
tic acid on sensory neurons. However, endogenous
mediators such as bradykinin, prostaglandins, and cyto-
kines (TNF-a and IL-1b), may indirectly also cause sen-
sory neurons sensitization and activation (Martinez et al.
1999). Oral administration of NOSH-aspirin reduced the
number of writhes and its effect was more potent than
aspirin. It is important to mention that in high doses
there is only a tendency of NOSH-aspirin to be more effi-
cacious that aspirin. The effect could be ascribed to the
inhibition of prostaglandins production as previously
shown (Chattopadhyay et al. 2012; Kodela et al. 2012).
Moreover, NOSH-aspirin-derived NO could also be mod-
ulating pain sensitivity. In fact, the antinociceptive effects
of several drugs in the acetic acid pain model are medi-
ated thought endogenous production of NO (Staurengo-
Ferrari et al. 2013).
In certain situations the analgesic effects of some drugs
upon acetic acid-induced writhing can be confused with
motor impairment or myorelaxant activities (Lopes et al.
2013). For NOSH-aspirin this is not the case, since it did
not cause any alterations in the rota-rod test, which is a
classical model to evaluate these unspecific effects (Ros-
land et al. 1990). Therefore, the antinociception effects of
NOSH-aspirin do not appear to be through peripheral
neuromuscular blockade or induction of sedation.
We also used Cg- and CFA-induced inflammatory hy-
peralgesia to assess the antinociceptive effects of NOSH-
aspirin. Whereas the paw injection of Cg promotes acute
inflammatory hyperalgesia which are very useful for
mechanism of action studies, the CFA model is clinically
more relevant due to its chronic character (Colpaert
1987). In fact, CFA-induced paw inflammation is accom-
panied by hyperalgesia, which is robust over several days
(Ma and Woolf 1996). Furthermore, CFA-induced
inflammatory hyperalgesia may be used to evaluate the
pharmacokinetic profile of antinociceptive drugs. In this
context, using the CFA-induced hyperalgesia it was possi-
ble to ascertain that NOSH-aspirin had an effect when
given 24 h after stimulus injection, suggesting a therapeu-
tic effect. In this model the antinociceptive effect of
NOSH-aspirin seems to be longer lasting than aspirin.
(A) (B)
Figure 6. Effect of NOSH-aspirin (NOSH-ASA) and aspirin on PGE2-induced hyperalgesia: involvement of KATP. (A) Mice were pretreated 50 min
before with aspirin (150 lmol/kg), NOSH-ASA (150 lmol/kg) or vehicle (v) orally followed by intraplantar (i.p.) injection of PGE2. Mechanical
hyperalgesia was evaluated 60 min after PGE2 injection. (B) Mice were pretreated with KATP blocker (glibenclamide; 10 mg/kg, i.p.) and after
30 min, they received vehicle or NOSH-ASA (150 lmol/kg), and after 50 min all groups received i.p. injection of PGE2. Mechanical hyperalgesia
was evaluated 60 min after PGE2 injection. Data are the means  SEM (n = 6). **P < 0.01 and ***P < 0.001 versus vehicle group, #P < 0.001
versus NOSH-ASA-treated group. KATP, ATP-sensitive potassium channel; PGE2, prostaglandin E2.
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Page 8
ª 2015 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
NOSH-Aspirin Reduces Inflammatory Pain M. D. Fonseca et al.
The mechanisms involved in the sensitization of the
primary sensory neurons, and consequently in the estab-
lishment of inflammatory hypernociception, may be
divided into two phases. The first involves the nonneuro-
nal events: the resident and migratory immune cells pro-
duce a vast number of hypernociceptive inflammatory
mediators including pronociceptive cytokines TNF-a,
IL-1b, and chemokines, nerve growth factor, and kinins,
which trigger the release of directly acting hyperalgesic
mediators (Verri et al. 2006). These mediators are consid-
ered direct acting because they activate their specific
receptors on the membrane of primary nociceptive neu-
rons (Cunha et al. 2005). Prostaglandins are known to be
direct-acting hyperalgesic mediators. The second phase
includes neuronal events: activation of the receptors on
primary nociceptive neurons by direct-acting mediators
leading to enhanced neuron excitability (Aley and Levine
1999). In order to elucidate the possible mechanisms by
which NOSH-aspirin is superior to aspirin in inhibiting
inflammatory hyperalgesia, initially the impact of NOSH-
aspirin on the production of pronociceptive cytokines
and neutrophil migration was determined. Firstly, NOSH-
aspirin’s-enhanced antinociceptive effect was not associ-
ated with reduction in neutrophil migration. These results
might reflect the fact that NSAIDs do not interfere with
leukocyte migration, but inhibit inflammatory hyperalge-
sia (Moncada et al. 1973; Lukkarinen et al. 2006). Fur-
thermore, whereas NO is an important inhibitor of
neutrophil migration to inflammatory site, H2S donors
seems to enhance neutrophil migration in Cg-induced
paw inflammation (Dal Secco et al. 2003; Bhatia et al.
2005; Cunha and Verri 2007). Thus, with NOSH-aspirin
there appears to be a balance between pro- and antineutr-
ophil migration factors and in the last instance neutrophil
migration is not altered. Nevertheless, it is noteworthy
that the effects of NO and H2S upon neutrophil migra-
tion is concentration dependent (Bhatia et al. 2005; Dist-
rutti et al. 2006b; Li et al. 2006; Kawabata et al. 2007;
Cunha et al. 2008a).
Inflammatory hyperalgesia is mediated by the produc-
tion of a cascade of pronociceptive cytokines/chemokines,
including TNF-a, IL-b, and KC/CXCCL1 (Cunha et al.
2005, 2008b). Further evaluating the mechanisms by
which NOSH-aspirin is different to aspirin, their effect
upon Cg-induced pronociceptive cytokines release was
determined. Interestingly, whereas both did not alter the
in vivo production of TNF-a and KC/CXCCL1, NOSH-
aspirin, but not aspirin, was able to reduce the produc-
tion/release of IL-1b. Although, we have previously shown
that NaHS, another H2S donor, did not reduce the pro-
duction of any of these cytokines in the mice paw during
Cg-induced paw inflammation (Cunha et al. 2008a), the
literature suggests that H2S can modulate pronociceptive
cytokines production (Li et al. 2008; Lee et al. 2013). In
addition, there is evidence that drugs, which promote
peripheral antinociceptive action through increases in
NO, modulate the production of IL-1b (Zarpelon et al.
2013). Moreover, NO-releasing NSAIDs reduce the activa-
tion of NF-jB, which is an important transcription factor
involved in the production of IL-1b (Chattopadhyay et al.
2010; Lee et al. 2013). Thus, the effect of NOSH-aspirin
on IL-1b production could be ascribed to the released
NO, or even by an additive (or synergistic) effect of both.
The main mechanism by which NSAIDs reduce inflam-
matory hyperalgesia is inhibiting the production of
inflammatory mediators (Ferreira 1972), and preventing
the sensitization of primary nociceptive neurons (Ferreira
1972; Moncada et al. 1975). However, there are some
analgesics that act on the periphery, thus directly blocking
nociceptive neurons sensitization (Ferreira et al. 1991;
Duarte et al. 1992). These analgesics have the characteris-
tics of inhibiting PGE2-induced hyperalgesia, suggesting
they might be restoring neuronal excitability (Alves et al.
2004; Cunha et al. 2010). This appears to be the case for
NOSH-aspirin, because it reduced the production of
pronociceptive cytokines and inhibited mechanical hyper-
algesia triggered by PGE2. In agreement, NO- and H2S-
donors unlike NSAIDs are able to reduce PGE2-induced
hyperalgesia (Cunha et al. 2008a, 2010).
The mechanism by which NOSH-aspirin and other
H2S-donors inhibit PGE2-induced hyperalgesia seems to
be dependent on upregulation of KATP currents in the
primary nociceptive neurons (Distrutti et al. 2006a;
Cunha et al. 2008a, 2010), leading to the hyperpolariza-
tion of primary nociceptive neurons (Cunha et al. 2010).
There are also data showing that H2S hyperpolarizes dor-
sal raphe neurons by activating the ATP-sensitive KATP
channels (Moore et al. 2003). Thus, the potent and effica-
cious effect of NOSH-aspirin against inflammatory pain
is due to its ability to prevent and restore nociceptive
neurons sensitization. Although our main hypothesis is
that NOSH-aspirin is acting peripherally to reduce
inflammatory pain, we must also acknowledge that it
could be promoting analgesia by acting centrally. In this
context, we like to point out a recent study by Distrutti
et al. (2010) suggesting that the antinociception effects of
H2S in a rodent model of visceral pain was modulated by
the transactivation of mu opioid receptors.
From a therapeutic point of view, it should be stressed
that NSAIDs can have serious side effects including GI,
cardiovascular, and renal (Kashfi 2009). Several studies
have shown that H2S and NO are important mediators of
gastric mucosal protection (Phillipson et al. 2003;
Fiorucci et al. 2006). In agreement with these findings,
NOSH-aspirin which releases both NO and H2S (Chatto-
padhyay et al. 2012; Kodela et al. 2012) has been shown
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to be safe to the stomach (Nia et al. 2013). It addition to
its GI safety, NOSH-aspirin might also prove to have
enhanced cardiovascular and renal safety profiles. This is
because NO and H2S have protective roles in the cardio-
vascular and renal system (Wallace et al. 2002; Huledal
et al. 2005; Rossoni et al. 2010).
In summary, the present results indicate that NOSH-
aspirin offers greater potency than aspirin in reducing
inflammatory pain in several clinically relevant models.
The enhanced antinociceptive effect of NOSH-aspirin
appears to be due to its ability to reduce the production
of pronociceptive cytokines such as IL-1b. Furthermore,
NOSH-aspirin is also able to reduce hyperalgesia, caused
by a directly acting hyperalgesic mediator in a mechanism
dependent on modulation of KATP channels. In conclu-
sion, we would like to suggest that NOSH-aspirin repre-
sents a prototype of a new class of analgesic drugs with
more potent effects than the traditional NSAID, aspirin.
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